FDA Issues Guidance on Biosimilar Labeling
The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.
Europe Phases Out COVID-19 Flexible Regulations
EMA, the European Commission, and HMAs are phasing out the flexible regulations put into place during the pandemic.